Search results
Results from the WOW.Com Content Network
The Ccd and parD systems are found to be strikingly similar in terms of their structures and actions. The antitoxin protein of each system interacts with its cognate toxin to neutralise the activity of the toxin and in the process the complex of the two becomes an efficient transcription repressor. [6]
Type II toxin-antitoxin systems are generally better-understood than type I. [39] In this system a labile proteic antitoxin tightly binds and inhibits the activity of a stable toxin. [10] The largest family of type II toxin-antitoxin systems is vapBC , [ 53 ] which has been found through bioinformatics searches to represent between 37 and 42% ...
It was the first type I toxin-antitoxin pair to be identified through characterisation of a plasmid-stabilising locus. [1] It is a type I system because the toxin is neutralised by a complementary RNA, rather than a partnered protein (type II toxin-antitoxin). [2] The conserved secondary structure of sok non-coding RNA transcript which binds ...
Toxic shock syndrome toxin-1 (TSST-1) is a superantigen with a size of 22 kDa [1] produced by 5 to 25% of Staphylococcus aureus isolates. It causes toxic shock syndrome (TSS) by stimulating the release of large amounts of interleukin-1, interleukin-2 and tumor necrosis factor. In general, the toxin is not produced by bacteria growing in the ...
Proteic addiction modules use proteins as toxins and antitoxins, as opposed to RNA or other methods. The known proteic addiction modules all have similar shared characteristics, including placement of the antitoxin gene relative to the toxin gene, method of toxin neutralization by the antitoxin, and autoregulation of the addiction module by the antitoxin or toxin:antitoxin complex.
This procedure involves injecting an animal with a safe amount of a particular toxin. The animal's body then makes the antitoxin needed to neutralize the toxin. Later, blood is withdrawn from the animal. When the antitoxin is obtained from the blood, it is purified and injected into a human or other animal, inducing temporary passive immunity.
The toxin is usually an AB toxin, a cytotoxic protein derived from a bacterial or plant protein, from which the natural binding domain has been removed so that the Fv directs the toxin to the antigen on the target cell. [1] Sometimes recombinant fusion proteins containing a toxin and a growth factor are also referred to as recombinant ...
Early administration of BAT is considered critical as the antitoxin can neutralize only circulating toxin, not toxin that has become bound to nerve terminals. [citation needed] One vial (20 mL) of BAT is administered to a patient as an intravenous infusion. It must be diluted with 0.9% sodium chloride in a 1:10 ratio before use.